Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.
Mr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.
$Olema Pharmaceuticals(OLMA.US)$Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers